Cambrex Corporation, a life sciences company, provides various products and services for the development and commercialization of new and generic therapeutics worldwide. Its products comprise active pharmaceutical ingredients and pharmaceutical intermediates that are used in the production of prescription and over-the-counter drug products, as well as finished dosage forms.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryLife Sciences Tools & Services
SectorMedical
Phone201-804-3000
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$532.09 million
Profitability
Miscellaneous
Employees1,732
Next Earnings Date11/14/2019 (Estimated)
OptionableOptionable
Cambrex (NYSE:CBM) Frequently Asked Questions
What is Cambrex's stock symbol?
Cambrex trades on the New York Stock Exchange (NYSE) under the ticker symbol "CBM."
How were Cambrex's earnings last quarter?
Cambrex Co. (NYSE:CBM) announced its earnings results on Thursday, August, 2nd. The biotechnology company reported $0.74 earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of $0.69 by $0.05. The biotechnology company earned $152.05 million during the quarter, compared to analyst estimates of $132.78 million. Cambrex had a net margin of 9.41% and a return on equity of 8.20%. Cambrex's revenue was up 13.0% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.76 EPS. View Cambrex's Earnings History.
When is Cambrex's next earnings date?
What price target have analysts set for CBM?
5 analysts have issued 1 year price objectives for Cambrex's shares. Their forecasts range from $43.00 to $60.00. On average, they expect Cambrex's stock price to reach $52.40 in the next year. This suggests that the stock has a possible downside of 12.2%. View Analyst Price Targets for Cambrex.
What is the consensus analysts' recommendation for Cambrex?
5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cambrex in the last year. There are currently 4 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Cambrex.
Has Cambrex been receiving favorable news coverage?
Headlines about CBM stock have trended negative recently, according to InfoTrie. InfoTrie scores the sentiment of news coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Cambrex earned a daily sentiment score of -2.6 on InfoTrie's scale. They also assigned media headlines about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the company's share price in the near term. View News Stories for Cambrex.
Are investors shorting Cambrex?
Cambrex saw a drop in short interest in the month of September. As of September 30th, there was short interest totalling 1,110,000 shares, a drop of 9.0% from the August 30th total of 1,220,000 shares. Based on an average daily volume of 694,300 shares, the days-to-cover ratio is presently 1.6 days. Approximately 3.3% of the shares of the company are short sold. View Cambrex's Current Options Chain.
Who are some of Cambrex's key competitors?
Some companies that are related to Cambrex include Teva Pharmaceutical Industries (TEVA), Perrigo (PRGO), SAGE Therapeutics (SAGE), Catalent (CTLT), Bausch Health Companies (BHC), Jazz Pharmaceuticals (JAZZ), Sarepta Therapeutics (SRPT), Dr.Reddy's Laboratories (RDY), ACADIA Pharmaceuticals (ACAD), Beigene (BGNE), Amarin (AMRN), Horizon Therapeutics (HZNP), The Medicines (MDCO), Ascendis Pharma A/S (ASND) and GW Pharmaceuticals PLC- (GWPH).
What other stocks do shareholders of Cambrex own?
Who are Cambrex's key executives?
Cambrex's management team includes the folowing people:
- Mr. Steven M. Klosk, Pres, CEO & Director (Age 62)
- Mr. Gregory P. Sargen, Exec. VP of Corp. Devel. & Strategy and CFO (Age 53)
- Mr. Shawn P. Cavanagh, Exec. VP & COO (Age 53)
- Ms. Samantha M. Hanley, VP, Gen. Counsel & Corp. Sec. (Age 41)
- Mr. James G. Farrell, VP & Corp. Controller (Age 52)
Who are Cambrex's major shareholders?
Cambrex's stock is owned by many different of institutional and retail investors. Top institutional shareholders include State of Alaska Department of Revenue (0.08%). Company insiders that own Cambrex stock include Gregory Sargen, Ilan Kaufthal, Samantha Hanley, Shawn Cavanagh, Steven M Klosk and Tom George Vadaketh. View Institutional Ownership Trends for Cambrex.
Which major investors are buying Cambrex stock?
How do I buy shares of Cambrex?
Shares of CBM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Cambrex's stock price today?
One share of CBM stock can currently be purchased for approximately $59.66.
How big of a company is Cambrex?
Cambrex has a market capitalization of $2.01 billion and generates $532.09 million in revenue each year. The biotechnology company earns $92.41 million in net income (profit) each year or $2.77 on an earnings per share basis. Cambrex employs 1,732 workers across the globe.View Additional Information About Cambrex.
What is Cambrex's official website?
How can I contact Cambrex?
Cambrex's mailing address is ONE MEADOWLANDS PLZ, EAST RUTHERFORD NJ, 07073. The biotechnology company can be reached via phone at 201-804-3000 or via email at [email protected]
MarketBeat Community Rating for Cambrex (NYSE CBM)
MarketBeat's community ratings are surveys of what our community members think about Cambrex and other stocks. Vote "Outperform" if you believe CBM will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CBM will underperform the S&P 500 over the long term. You may vote once every thirty days.
